At a press conference at SABCS 2014, Prof Robertson discusses the results of the phase II FIRST trial, which compared overall survival with fulvestrant versus anastrozole as first-line treatment for patients with advanced hormone receptor-positive breast cancer:
Those patients who took fulvestrant lived longer than those who took anastrozole.
Read the news story or watch the interview here.